{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:16Z","timestamp":1790665636512,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Total metabolic tumor volume (TMTV) is a promising quantitative biomarker for therapy assessment and prognosis in Hodgkin Lymphoma affected patients that allows prediction of patient outcome. The aim of this study was to evaluate the TMTV reproducibility between different sources of variability in tumor delimitation such as SUV-based thresholds (2.5, 41% and 50%) and software tools (Beth Israel plugin (BI) and LIFEx). Effect of contouring procedure both including single and multiple regions of interest was also studied in patients with multiple lesions, and optimal cut-offs for each studied method were displayed to compare the effect on prognosis. Strong alikeness in TMTV was found for 2.5 under software choice<jats:italic>.<\/jats:italic> Best accuracy in contouring compared to visual assessment of the disease was found for BI multiple ROI and LIFEx single ROI drawing. Similar cut-offs were found between both software for all considered thresholds, but best resemblance and highest cut-off due to an overestimation of the TMTV was found for 2.5 SUV. Our findings suggest that optimal reproducibility in TMTV is found for SUV\u2009&gt;\u20092.5 threshold under choice of contouring methodology or software tool, meaning that overestimation of the TMTV threshold using 2.5 looks to be preferable than underestimation with 41% and 50%.<\/jats:p>","DOI":"10.1038\/s41598-020-69577-9","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T10:04:50Z","timestamp":1595930690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of different automatic methods for the delineation of the total metabolic tumor volume in I\u2013II stage Hodgkin Lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Queralt","family":"Mart\u00edn-Saladich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Reyn\u00e9s-Llompart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Sabat\u00e9-Llobera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azahara","family":"Palomar-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Cort\u00e9s-Romera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"69577_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","volume":"77","author":"JM Zaucha","year":"2019","unstructured":"Zaucha, J. M., Chauvie, S., Zaucha, R., Biggii, A. & Gallamini, A. The role of PET\/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat. Rev. 77, 44\u201356 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"69577_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu, L. & Chauvie, S. Metabolic tumor volume metrics in lymphoma. Semin. Nucl. Med. 48, 50\u201366 (2018).","journal-title":"Semin. Nucl. Med."},{"key":"69577_CR3","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin, C. et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J. Nucl. Med. 48, 1626\u20131632 (2007).","journal-title":"J. Nucl. Med."},{"key":"69577_CR4","doi-asserted-by":"publisher","DOI":"10.1109\/NSSMIC.2013.6829383","author":"F Gallivanone","year":"2013","unstructured":"Gallivanone, F. et al. Adaptive threshold method based on PET measured lesion-to-background ratio for the estimation of Metabolic Target Volume from 18F-FDG PET images. IEEE Nucl. Sci. Symp. Conf. Rec. https:\/\/doi.org\/10.1109\/NSSMIC.2013.6829383 (2013).","journal-title":"IEEE Nucl. Sci. Symp. Conf. Rec."},{"key":"69577_CR5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227249","author":"SF Barrington","year":"2019","unstructured":"Barrington, S. F. & Meignan, M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.119.227249 (2019).","journal-title":"J. Nucl. Med."},{"key":"69577_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun, S. et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma. PLoS ONE 10, 1\u201315 (2015).","journal-title":"PLoS ONE"},{"key":"69577_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-5","author":"D Tseng","year":"2012","unstructured":"Tseng, D. et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin\u2019s disease. Radiat. Oncol. https:\/\/doi.org\/10.1186\/1748-717X-7-5 (2012).","journal-title":"Radiat. Oncol."},{"key":"69577_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328\u2013354 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"69577_CR9","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche, C. et al. Lifex: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 78, 4786\u20134789 (2018).","journal-title":"Cancer Res."},{"key":"69577_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press, O. W. et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J. Clin. Oncol. 34, 2020\u20132027 (2016).","journal-title":"J. Clin. Oncol."},{"key":"69577_CR11","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/cas.12282","volume":"104","author":"MK Song","year":"2013","unstructured":"Song, M. K. et al. Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin\u2019s lymphoma. Cancer Sci. 104, 1656\u20131661 (2013).","journal-title":"Cancer Sci."},{"key":"69577_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.135","author":"AM Evens","year":"2014","unstructured":"Evens, A. M. & Kostakoglu, L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology https:\/\/doi.org\/10.1182\/asheducation-2014.1.135 (2014).","journal-title":"Hematology"},{"issue":"52","key":"69577_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"2010","author":"HJ Im","year":"2018","unstructured":"Im, H. J., Bradshaw, T., Solaiyappan, M. & Cho, S. Y. Current methods to define metabolic tumor volume in positron emission tomography: which one is better?. Nucl. Med. Mol. Imaging 2010(52), 5\u201315 (2018).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"69577_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2967\/jnumed.116.180406","volume":"58","author":"AS Cottereau","year":"2017","unstructured":"Cottereau, A. S. et al. Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma. J. Nucl. Med. 58, 276\u2013281 (2017).","journal-title":"J. Nucl. Med."},{"key":"69577_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi, Y. E. et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80, 2505\u20132509 (1997).","journal-title":"Cancer"},{"key":"69577_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00259-018-3938-y","volume":"45","author":"C Lasnon","year":"2018","unstructured":"Lasnon, C., Enilorac, B. & Aide, N. Reply to: \u201cAll that glitters is not gold \u2013 new reconstruction methods using Deauville criteria for patient reporting\u201d. Eur. J. Nucl. Med. Mol. Imaging 45, 878\u2013881 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"69577_CR17","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/mp.12986","volume":"45","author":"G Reyn\u00e9s-Llompart","year":"2018","unstructured":"Reyn\u00e9s-Llompart, G. et al. Phantom, clinical, and texture indices evaluation and optimization of a penalized-likelihood image reconstruction method (Q Clear) on a BGO PET\/CT scanner. Med. Phys. 45, 3214\u20133222 (2018).","journal-title":"Med. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69577-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69577-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69577-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:41:53Z","timestamp":1670337713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69577-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69577"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69577-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12590"}}